MUFG Americas’s TG Therapeutics TGTX Stock Holding History

MUFG Americas’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,206	Closed	-$6K	–	1182
2016 Q4	$6K	Sell	1,206 -377	-24%	-$2.21K	﹤0.01%	920
2016 Q3	$12K	Hold	1,583	–	–	﹤0.01%	824
2016 Q2	$10K	Buy	+1,583	New	+$12.9K	﹤0.01%	849

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MUFG Americas's TGTX Position: Q1 2017 in Review

MUFG Americas sold out of TG Therapeutics (TGTX) in Q1 2017, closing a stake of 1,206 shares — an estimated $6K sold.

MUFG Americas first reported a position in TGTX in Q2 2016 and held it in 3 quarters. The position peaked at $12K in Q3 2016. 97 funds tracked by Wall St. Rank hold TGTX as of Q1 2017.

MUFG Americas reported no remaining TG Therapeutics position as of Q1 2017 after selling out during the quarter.
MUFG Americas sold 1,206 TG Therapeutics shares in Q1 2017, an estimated $6K.
MUFG Americas first reported a position in TG Therapeutics in Q2 2016 and held it in 3 quarters.
MUFG Americas's TG Therapeutics position peaked at $12K in Q3 2016.
97 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2017.

Based on MUFG Americas's 13F filing for Q1 2017, filed 4 May 2017.